173 related articles for article (PubMed ID: 15453926)
1. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
Venkatesh H; Di Bella N; Flynn TP; Vellek MJ; Boehm KA; Asmar L
Clin Lymphoma; 2004 Sep; 5(2):110-5. PubMed ID: 15453926
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Emmanouilides C; Colovos C; Pinter-Brown L; Hernandez L; Schiller G; Territo M; Rosen P
Clin Lymphoma; 2004 Jun; 5(1):45-9. PubMed ID: 15245607
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Oki Y; Pro B; Fayad LE; Romaguera J; Samaniego F; Hagemeister F; Neelapu S; McLaughlin P; Goy A; Younes A
Cancer; 2008 Feb; 112(4):831-6. PubMed ID: 18085611
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.
Fosså A; Santoro A; Hiddemann W; Truemper L; Niederle N; Buksmaui S; Bonadonna G; Seeber S; Nowrousian MR
J Clin Oncol; 1999 Dec; 17(12):3786-92. PubMed ID: 10577850
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M; Avigdor A; Ribakovsky E; Nagler A; Kedmi M
Acta Haematol; 2019; 141(2):84-90. PubMed ID: 30630175
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Chau I; Harries M; Cunningham D; Hill M; Ross PJ; Archer CD; Norman AR; Wotherspoon A; Koh DM; Gill K; Uzzell M; Prior Y; Catovsky D
Br J Haematol; 2003 Mar; 120(6):970-7. PubMed ID: 12648066
[TBL] [Abstract][Full Text] [Related]
10. A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.
Validire P; Fermé C; Brice P; Diviné M; Gabarre J; Bouabdallah K; Fitoussi O; Chaoui D; Pacquement H; Soussain C; Carde P; Salhi R; Zanni M; Decaudin D
Anticancer Drugs; 2008 Mar; 19(3):309-15. PubMed ID: 18510178
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
Masters GA; Declerck L; Blanke C; Sandler A; DeVore R; Miller K; Johnson D;
J Clin Oncol; 2003 Apr; 21(8):1550-5. PubMed ID: 12697880
[TBL] [Abstract][Full Text] [Related]
13. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
Hoang T; Kim K; Jaslowski A; Koch P; Beatty P; McGovern J; Quisumbing M; Shapiro G; Witte R; Schiller JH
Lung Cancer; 2003 Oct; 42(1):97-102. PubMed ID: 14512193
[TBL] [Abstract][Full Text] [Related]
15. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Naqi N; Ahmad S; Shah I; Khattak J
J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
[TBL] [Abstract][Full Text] [Related]
16. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
Hawkes EA; Barton S; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Horwich A; Potter M; Ethel M; Dearden C; Chau I
Ann Hematol; 2014 May; 93(5):827-34. PubMed ID: 24158386
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
Santoro A; Bredenfeld H; Devizzi L; Tesch H; Bonfante V; Viviani S; Fiedler F; Parra HS; Benoehr C; Pacini M; Bonadonna G; Diehl V
J Clin Oncol; 2000 Jul; 18(13):2615-9. PubMed ID: 10893294
[TBL] [Abstract][Full Text] [Related]
19. Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.
Zhong DT; Shi CM; Chen Q; Huang JZ; Liang JG
Ann Hematol; 2012 Nov; 91(11):1757-63. PubMed ID: 22790106
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
Offidani M; Mele A; Corvatta L; Marconi M; Malerba L; Olivieri A; Rupoli S; Alesiani F; Leoni P
Leuk Lymphoma; 2002 Jun; 43(6):1273-9. PubMed ID: 12152996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]